LDL-C and Lp(a) act as separate causative drivers of ASCVD risk, with Lp(a) introducing a genetically determined orthogonal risk axis (Cardiol Rev 2026)

Original title: LDL-C vs Lp(a): What We Know, the "Zero-LDL" Hypothesis, and Where We Stand in the PCSK9 Era

Cardiol Rev · 23 September 2026 · 5

Anamika F, Dawar P, Aggarwal K, Dixit S, Kugalur Saravanan G, Nanjundappa A

This narrative review compares the pathophysiology, epidemiology, and clinical risk of LDL-C/apoB versus Lp(a). It synthesizes randomized trials, Mendelian randomisation studies, and population cohorts to establish that both particles are independent causative drivers of atherosclerotic cardiovascular disease. The authors argue that Lp(a) represents an orthogonal, genetically determined risk axis distinct from lifestyle-modifiable LDL-C. They propose a dual-axis prevention strategy targeting cumulative apoB load alongside genetically driven Lp(a) risk, positioning PCSK9 inhibitors and upcoming dedicated Lp(a)-lowering agents within modern therapeutic frameworks. The review provides a structured orientation for clinicians managing complex lipid profiles.

Original abstract

Despite significant breakthroughs in preventative medicine, atherosclerotic cardiovascular disease (ASCVD) is still the primary cause of morbidity and death worldwide. In this context, 2 apoB-containing particles-LDL and lipoprotein(a) [Lp(a)] have emerged as important but mechanistically separate causes of atherothrombotic illness. This review synthesizes current knowledge in lipid biology, epidemiology, measurement, and therapeutics to address 3 key questions: (1) how LDL-C/apoB and Lp(a) differ in structure, pathophysiology, and clinical risk; (2) what the evidence shows about the safety and efficacy of driving LDL-C to very low or near-zero levels; and (3) where PCSK9-based therapies and soon, dedicated Lp(a) -lowering agents-fit into modern prevention strategies. Randomized trials, MR studies, and population-level cohort data all contribute to a clear and convincing picture: LDL-C/apoB and Lp(a) are separate causative drivers of cardiovascular risk, with Lp(a) introducing an orthogonal risk axis determined by genetics rather than lifestyle. By combining both viewpoints, we propose a feasible, dual-axis strategy to ASCVD prevention that addresses both cumulative apoB load and genetically driven Lp(a) risk.

Summary written by lp-a.org from the published abstract; figures as published. Page updated 26 September 2026. Methods.